Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transcode Therapeutics Inc (NQ: RNAZ )

0.8291 +0.0991 (+13.58%)
Streaming Delayed Price Updated: 2:35 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Transcode Therapeutics Inc

< Previous 1 2 3 Next >
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option
From TransCode Therapeutics, Inc.
Via Business Wire
TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering
From TransCode Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.